Groups

Research Focus

Information Systems; Applications Specialist I

Recent additions – View all

1. Healthcare resource utilization (HCRU) and costs for patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (LOT1) pembrolizumab plus axitinib (P+A) or ipilimumab plus nivolumab (I+N)

   Meeting Abstract

   Shah, N. J.; Shinde, R.; Moore, K.; Sainski-Nguyen, A.; Le, L.; Cao, F.; Song, R.; Singhal, P.; Motzer, R. J.
   Journal of Clinical Oncology (2022)

   Fulltext@MSK | Save
2. Impact of the Paris System for Reporting Urinary Cytology atypical urothelial cells category at a major cancer center

   Meeting Abstract

   Guo, T.; Alex, D.; Rudomina, D.; Cao, F.; Lin, O.
   Modern Pathology (2018)

   Fulltext@MSK | Save